[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ: JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol; 2010 Jan;62(1):145-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We studied the effect of JS-K on angiogenesis in human umbilical vein endothelial cells (HUVECs), OPM1 multiple myeloma cells, chick aortic rings and in mice.
  • In the chick aortic ring assay using VEGF or FGF-2 for vessel growth stimulation, 0.5 microm JS-K completely inhibited vessel growth.
  • As such, it establishes a new class of antineoplastic agent that targets the malignant cells directly as well as their microenvironment.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):189-97 [10607702.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 10;391(1-2):137-44 [10720645.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3111-6 [10955791.001]
  • [Cites] J Org Chem. 2001 May 4;66(9):3090-8 [11325274.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):32-40 [12507958.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):409-17 [12700285.001]
  • [Cites] Proteomics. 2003 May;3(5):714-23 [12748950.001]
  • [Cites] Bone Marrow Transplant. 2004 Aug;34(3):235-9 [15170170.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4813-21 [15269157.001]
  • [Cites] Cancer Treat Rev. 2004 Oct;30(6):495-513 [15325031.001]
  • [Cites] Pharmacol Rev. 1991 Jun;43(2):109-42 [1852778.001]
  • [Cites] FASEB J. 1992 Sep;6(12):3051-64 [1381691.001]
  • [Cites] Blood. 1992 Oct 15;80(8):1880-4 [1382708.001]
  • [Cites] Baillieres Clin Haematol. 1992 Oct;5(4):943-60 [1364045.001]
  • [Cites] Br J Pharmacol. 1994 Mar;111(3):894-902 [7517330.001]
  • [Cites] Leuk Res. 1995 Aug;19(8):527-33 [7658698.001]
  • [Cites] Drug Metab Rev. 1997 Feb-May;29(1-2):59-77 [9187511.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1461-6 [9737697.001]
  • [Cites] Adv Exp Med Biol. 1999;457:205-9 [10500795.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):501-8 [16288082.001]
  • [Cites] J Med Chem. 2006 Jul 13;49(14):4356-66 [16821795.001]
  • [Cites] Blood. 2007 Jul 15;110(2):709-18 [17384201.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612 [18070708.001]
  • [Cites] Antioxid Redox Signal. 2008 Nov;10(11):1941-88 [18774901.001]
  • [Cites] Genomics. 2009 Jul;94(1):32-8 [19348908.001]
  • (PMID = 20723011.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084496-03; United States / NCI NIH HHS / CA / R01 CA084496-02; United States / NCI NIH HHS / CA / R01 CA84496; United States / NCI NIH HHS / CA / R01 CA084496; United States / NCI NIH HHS / CA / R01 CA129611-02; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA129611-01A1; United States / NCI NIH HHS / CA / CA084496-01A2; United States / NCI NIH HHS / CA / CA129611-02; United States / NCI NIH HHS / CA / CA129611-01A1; United States / NCI NIH HHS / CA / CA084496-02; United States / NCI NIH HHS / CA / R01 CA084496-03; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CA / R01 CA129611; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / R01 CA084496-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Azo Compounds; 0 / O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate; 0 / Piperazines
  • [Other-IDs] NLM/ NIHMS165373; NLM/ PMC2925308
  •  go-up   go-down


2. El Hour M, Moncada-Pazos A, Blacher S, Masset A, Cal S, Berndt S, Detilleux J, Host L, Obaya AJ, Maillard C, Foidart JM, Ectors F, Noel A, Lopez-Otin C: Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene; 2010 May 20;29(20):3025-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis.
  • By applying three different in vivo models of angiogenesis (malignant keratinocyte transplantation, Matrigel plug and aortic ring assays) to Adamts12(-/-) mice, we provide evidence for a protective effect of this host enzyme toward angiogenesis and cancer progression.
  • In the absence of Adamts-12, both the angiogenic response and tumor invasion into host tissue were increased.
  • Complementing results were obtained by using medium conditioned by cells overexpressing human ADAMTS-12, which inhibited vessel outgrowth in the aortic ring assay.
  • This angioinhibitory effect of ADAMTS-12 was independent of its enzymatic activity as a mutated inactive form of the enzyme was similarly efficient in inhibiting endothelial cell sprouting in the aortic ring assay than the wild-type form.
  • Altogether, our results show that ADAMTS-12 displays antiangiogenic properties and protect the host toward tumor progression.
  • [MeSH-major] ADAM Proteins / physiology. Neoplasms, Experimental / blood supply. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Aorta / cytology. Aorta / metabolism. Collagen / metabolism. Collagen Type I / metabolism. Drug Combinations. Female. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Keratinocytes / transplantation. Laminin / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Neoplasm Invasiveness. Proteoglycans / metabolism. Rats. Rats, Wistar

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208563.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / Adamts12 protein, mouse
  •  go-up   go-down


3. Aguilar-Olivos NE, García-Ortiz JR, Rojas-Reyna GA, Chaparro-González JM, Weisser-Jacobs F, Oria-Hernández J: [Relevance of nuclear medicine in the diagnosis and treatment of malignant paraganglioma]. Cir Cir; 2009 May-Jun;77(3):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of nuclear medicine in the diagnosis and treatment of malignant paraganglioma].
  • [Transliterated title] Relevancia de la medicina nuclear en el diagnóstico y tratamiento del paraganglioma maligno.
  • Their treatment depends on the extension and functional characteristics of the tumor.
  • In this pathology, the anatomic and functional diagnostic evaluations provided by nuclear medicine imaging studies have significant usefulness.
  • CLINICAL CASE: A 34-year-old male was diagnosed with a paraganglioma at the level of the aortic bifurcation by means of laboratory tests, imaging studies and nuclear medicine studies.
  • Nuclear medicine was carried out with a scintigraphy with a norepinephrine analog, radioactive meta-iodo-benzyl-guanidine (131I-MIBG), which demonstrates functionally and specifically the presence of neoplastic adrenergic tissue and extratumoral extension.
  • Nuclear medicine studies allow the diagnosis of a malignant paraganglioma with presence of bone metastasis.
  • The therapy includes surgical removal of the tumor and ablation of residual malignant tissue and metastatic lesions by radiotherapy with 131I-MIBG.
  • Radiotherapeutic treatment was possible due to the capacity of the tumor to uptake and to concentrate the radioactive hormonal analog.
  • CONCLUSIONS: In cases of paraganglioma, in addition to the localization of the tumor and the evaluation of biochemical alterations, it is indispensable to obtain anatomic and functional evaluation provided by nuclear medicine studies in order to achieve appropriate diagnoses and treatment.
  • [MeSH-major] Aorta, Abdominal. Paraganglioma / radionuclide imaging. Paraganglioma / surgery. Vascular Neoplasms / radionuclide imaging. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671277.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


Advertisement
4. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B: Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist; 2006 Jan;11(1):9-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The introduction of imatinib, an orally administered inhibitor of the KIT receptor tyrosine kinase, is prompting revision of the management algorithms that have traditionally guided the treatment of gastrointestinal stromal tumor (GIST).
  • Historically, patients with GISTs have had substantial rates of relapse as well as limited long-term survival even after complete surgical resection of a primary tumor.
  • Imatinib has been shown to induce durable tumor responses in more than half of the patients with malignant metastatic or unresectable GISTs and to halt disease progression in an additional third.
  • The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aortic Aneurysm, Abdominal / complications. Benzamides. Chemotherapy, Adjuvant. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy. Receptor, Platelet-Derived Growth Factor alpha / genetics. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401709.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 37
  •  go-up   go-down


5. Tóth L, Nemes Z, Gomba S, Asztalos L, Molnár C, András C, Szentirmay Z, Molnár P: Primary rhabdoid cancer of the ileum: a case report and review of the literature. Pathol Res Pract; 2010 Feb 15;206(2):110-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the first publication of a rhabdoid cancer, described as an infrequent variant of Wilms' tumor, several cases of extrarenal rhabdoid tumor have been reported in the literature.
  • An 81-year-old male patient was admitted to the Department of Internal Medicine with subileus and bloody stools.
  • Ileus-mandated laparotomy disclosed an obstructive tumor of the ileum.
  • Histological work-up of the numerous biopsies disclosed a cellular, solid, necrotic, hemorrhagic, and invasive tumor.
  • The overall appearance of the neoplasm was highly similar in every specimen.
  • The immunohistochemical phenotype of the malignant cells indicated rhabdoid characteristics.
  • This report aims to call the pathologist's attention to the differential diagnostic importance of this entity.
  • [MeSH-major] Ileal Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged, 80 and over. Angina Pectoris / complications. Antigens, CD / biosynthesis. Aortic Aneurysm, Abdominal / complications. Diverticulosis, Colonic / complications. Fatal Outcome. Heart Failure / complications. Hernia, Inguinal / complications. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local / pathology. Prostatic Hyperplasia / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for rhabdoid cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19369011.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 27
  •  go-up   go-down






Advertisement